Cocrystal Pharma Inc (COCP) - Total Liabilities
Based on the latest financial reports, Cocrystal Pharma Inc (COCP) has total liabilities worth $3.31 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Cocrystal Pharma Inc net asset momentum to track the company's year-over-year net asset growth rate.
Cocrystal Pharma Inc - Total Liabilities Trend (2007–2025)
This chart illustrates how Cocrystal Pharma Inc's total liabilities have evolved over time, based on quarterly financial data. See Cocrystal Pharma Inc (COCP) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Cocrystal Pharma Inc Competitors by Total Liabilities
The table below lists competitors of Cocrystal Pharma Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Connexion Mobility Ltd
AU:CXZ
|
Australia | AU$1.49 Million |
|
Pets at Home Group Plc
LSE:PETS
|
UK | GBX681.60 Million |
|
Pineapple Resources Bhd
KLSE:0006
|
Malaysia | RM5.36 Million |
|
Seamless Distribution Systems AB
ST:SDS
|
Sweden | Skr339.60 Million |
|
Cosmos Health Inc.
NASDAQ:COSM
|
USA | $47.05 Million |
|
Aurora Spine Corp
V:ASG
|
Canada | CA$6.09 Million |
|
Wong Engineering Corporation Bhd
KLSE:7050
|
Malaysia | RM54.95 Million |
|
The Motor & General Finance Limited
NSE:MOTOGENFIN
|
India | Rs843.31 Million |
Liability Composition Analysis (2007–2025)
This chart breaks down Cocrystal Pharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Cocrystal Pharma Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cocrystal Pharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cocrystal Pharma Inc (2007–2025)
The table below shows the annual total liabilities of Cocrystal Pharma Inc from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.38 Million | -14.04% |
| 2024-12-31 | $3.93 Million | -19.32% |
| 2023-12-31 | $4.88 Million | +282.95% |
| 2022-12-31 | $1.27 Million | -30.93% |
| 2021-12-31 | $1.84 Million | +6.10% |
| 2020-12-31 | $1.74 Million | -38.47% |
| 2019-12-31 | $2.82 Million | +68.64% |
| 2018-12-31 | $1.67 Million | -89.55% |
| 2017-12-31 | $16.03 Million | -28.98% |
| 2016-12-31 | $22.56 Million | -60.16% |
| 2015-12-31 | $56.64 Million | -77.58% |
| 2014-12-31 | $252.63 Million | +1923.90% |
| 2013-12-31 | $12.48 Million | +15.36% |
| 2012-12-31 | $10.82 Million | +4.89% |
| 2011-12-31 | $10.32 Million | +12412.60% |
| 2010-12-31 | $82.44K | +42.11% |
| 2009-12-31 | $58.01K | +38.59% |
| 2008-12-31 | $41.86K | +74.04% |
| 2007-12-31 | $24.05K | -- |
About Cocrystal Pharma Inc
Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hep… Read more